▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1096 by analyst upside · 2026-11-13
DSGN
Design Therapeutics, Inc.
Healthcare · Market Cap $678M · P/E 0x
ANALYST PRICE TARGET
+103.9%
implied upside to consensus target
Current Price $10.58
Consensus Target $21.57
Bull Target $26.0
Bear Target $19.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
0
Sell
0
52-Week Low $6.81
52-Week High $17.25
YTD Return +16.3%
FUNDAMENTALS
Market Cap $678M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.20
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $6.81
52-Week High $17.25
Current Price $10.58
Bear Target $19.0
Bull Target $26.0
● Now $10.58 ● Target $21.57
TRADING DATA
Avg Volume 581K
YTD Return +16.3%
Analyst Count 7
Consensus Buy
Upside to Target +103.9%
Last Updated 2026-11-13

ANALYST SUMMARY

Design Therapeutics, Inc. (DSGN) is currently trading at $10.58 with a Wall Street consensus price target of $21.57, implying potential upside of 103.9% over the next 12 months. 7 analysts currently cover DSGN, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $19.0.

DSGN operates in the Healthcare sector with a market capitalisation of $678M. The stock is up 16.3% year-to-date and is currently trading near the lower end of its 52-week range of $6.81 – $17.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ZVRA +126.3%
Zevra Therapeutics, Inc.
$664M · P/E 9.1x · Buy
BVS +52.9%
Bioventus Inc.
$744M · P/E 13.4x · Buy
COLL +79.9%
Collegium Pharmaceutical, Inc.
$775M · P/E 22.9x · Buy
ABUS +32.8%
Arbutus Biopharma Corporation
$618M · P/E 3.6x · Buy
RIGL +40.9%
Rigel Pharmaceuticals, Inc.
$860M · P/E 2.8x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for DSGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Outperform → Outperform 2026-11-05 Building track record
Wells Fargo ● Initiated
Overweight 2026-10-02 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-05-04 14% win rate (7 calls)
Jefferies ● Initiated
Buy 2026-03-16 50% win rate (6 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-03-10 Building track record
Oppenheimer ● Initiated
Outperform 2026-01-07 14% win rate (7 calls)
Leerink Partners ↑ Upgrade
Market Perform → Outperform 2025-12-03 29% win rate (7 calls)
RBC Capital ↑ Upgrade
Sector Perform → Outperform 2025-11-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
60
out of 100
Coverage depth
16/30
Consensus clarity
17/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →